TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Anastomotic leak at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Fall Risk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung deposition of budesonide (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lachmeter examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: International Knee Documentation score (IKDC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Elevated Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in KOOS Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ktrans Volume Transfer Constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Drug-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in accurately measured GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change Oppositional Defiant Disorder subscale score of the Symptom Checklist Disruptive Behavior Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change total score of the Symptom Checklist Attention-Deficit/Hyperactivity Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Oppositional Defiant Disorder subscale score of the Diagnostic Checklist Disruptive Behavior Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change total score of the Diagnostic Checklist Attention-Deficit/Hyperactivity Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the number of micronuceli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Resolution Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of alveolar bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who achieved the complete chemotherapy treatment sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spatial Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Seattle Angina Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventable Adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants Discontinuing Study Medication Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve alveolar concentration of desflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motricity score for hemiplegic upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugly Meyer motor score for upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Tissue Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI Measurements of Tendon Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tear Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Communication of cognitive challenges
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fever episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Development of t-AML/MDS
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Confirmed Evidence of Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Regulatory T Cells (Tregs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immediate procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vertical bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Volume Variance (SVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Poor health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: differences in DNA somatic mutational profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: differences in RNA sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need For Cognition (NFC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Personal Need for Structure (PNS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anxiety due to uncertainty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lingual Tonsil Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal Functional Assessment (MFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: construct validity of health-related needs assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: internal consistency of health-related needs assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: short-term stability of health-related needs assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Tesevatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Percent Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resolution of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of clinical efficacy-evaluable subjects with continued resolution at 30-day follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events as observed by the investigator
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs including blood pressures, pulse rate, and respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Titers of ZEBOV-specific IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Length of stay in Psychiatric Intensive Care Unit (PICU)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Symptoms of psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Violent or threatening incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of structural heart disease
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of structural heart disease
Endpoint domain: Mortality/survival
Primary endpoint: response rate or PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ex-vivo immunomodulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hardening of the arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Histological complete resection rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mother's post-traumatic reaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite index of serious postoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with HbA1c ≤ 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absence of severe hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in HbA1c of at least 1 point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Parents Activating Patient Portal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Children's Hope Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean volume of crow's feet wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Beta-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher Radiation Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Grade 4 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: peak maximum concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under recombinant G-CSF concentration curve versus time (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute neutrophil count (ANC) versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Faecal bacteria numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seven-day point prevalence smoking abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean blood pressure (systolic and diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean differences in depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mania PSR scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumer's perceptions of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycemic control assessed by HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual acuity change from the baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence with optical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time needed for resolution of fever and dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of chest drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 17-item Hamilton Rating Scale for Depression (HRSD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of detoxifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance between femoral vein and artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: neurobehavioral functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: sperm extraction success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cmax (Maximum Observed Concentration) - Amoxicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Observed Concentration) - Clavulanic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sf-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Baseline Startle Magnitude During Fear Conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Startle Magnitude to Danger Signal During Fear Conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Fear-potentiated Startle to Danger Signal During Early Extinction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Fear-potentiated Startle to Danger Signal During Late Extinction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baby weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary pharmacokinetics of GSK2140944
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pharmacokinetics of GSK2140944
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suicidal Behaviors and Ideations
Endpoint domain: Adverse events/effects
Primary endpoint: (A + B) grade sperm and sperm activity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: A grade sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increased Blood Sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients attaining LDL-C goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients attaining BP goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caffeine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Meeting IMACS Preliminary Definition of Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With COVID-19 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in lower limb functional level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change of blood concentration levels of fentanyl and nurofentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale Screener (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel lumen distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Systemic tobramycin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: change in motor disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p16INK4a staining pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HPV status of the initial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Warfarin Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in prophylactic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of heart failure patients
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline on the total score of the AMS rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Finger joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Michigan Hand Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of patients with esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: duration until onset of esophagitis (days)
Endpoint domain: Adverse events/effects
Primary endpoint: severity of esophagitis (NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0 score)
Endpoint domain: Adverse events/effects
Primary endpoint: Color Doppler parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post operative wavefront aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom score in response to insulin-induced hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative, Daily serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post operative, Daily creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ease of use of tablet-guided tobacco intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stapedius reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum hepcidin rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in subject's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall survival after diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Time to relapse or progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraoperative use of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the intima-media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Sero-reduction or Sero-conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence Rate of Seronegative Conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of Toric Rotation Away From Target Axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-Flow Variables during pharyngeal swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of intravenous DTIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieve a Global Response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Beta Band Oscillatory Power During Food-cue Visual Probe Attention Bias Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major ischemic cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of anxiety disorder diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Inattention Test (BIT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Mitral Regurgitation (MR) Reduction to ≤2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of Karonudib (TH1579)
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum Observed Plasma Concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative anesthesia emergence delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time (AUC0-τ) curve for OC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for OC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Enrolled Participants Who Actually Get Treated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in asthma clinical control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes